Role of genetics and drug metabolism in human cancer risk
- 30 April 1991
- journal article
- review article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 247 (2) , 267-281
- https://doi.org/10.1016/0027-5107(91)90022-g
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Structural Gene Products of the Murine Ah ComplexEuropean Journal of Biochemistry, 2005
- Lung Cancer and the Debrisoquine Metabolic PhenotypeJNCI Journal of the National Cancer Institute, 1990
- DEBRISOQUINE METABOLISM IN PARKINSONIAN PATIENTS TREATED WITH ANTIHISTAMINE DRUGSThe Lancet, 1987
- Role of aromatic amine acetyltransferase in human colorectal cancerArchives of Surgery, 1986
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985
- Molecular clock of silent substitution: At least six-fold preponderance of silent changes in mitochondrial genes over those in nuclear genesJournal of Molecular Evolution, 1982
- 2,3,7,8-Tetrachlorodibenzo-p-Dioxin and Related Halogenated Aromatic Hydrocarbons: Examination of the Mechanism of ToxicityAnnual Review of Pharmacology and Toxicology, 1982
- Some observations on the oxidation phenotype status of Nigerian patients presenting with cancerCancer Letters, 1981
- Questionable Relation of Aryl Hydrocarbon Hydroxylase to Lung-Cancer RiskNew England Journal of Medicine, 1977
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960